Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
| ▸ | VNN1 | O95497 | 13/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CHAT | P28329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pantethine SCHEMBL1650348 | 1.00 | PTGS1 (0.56) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL59597 | 1.00 | PTGS1 (0.56) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL19358994 | 0.99 | PTGS1 (0.55) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL19359043 | 0.99 | PTGS1 (0.55) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL8416070 | 0.99 | PTGS1 (0.55) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL9112817 | 0.97 | PTGS1 (0.54) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL9115760 | 0.97 | PTGS1 (0.54) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| Pantethine SCHEMBL8416043 | 0.96 | PTGS1 (0.52) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| SCHEMBL18314794 | 0.95 | PTGS1 (0.51) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 | |
| SCHEMBL22369798 | 0.95 | PTGS1 (0.51) | PTGS1KCNH2VNN1ZDHHC20ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310461-A1 | Compositions and Methods for Treatment of Prediabetes | CROSS III WILLIAM H (US) | 2023-10-05 | — | — | US | disclosed |
| US-20170312329-A1 | Compositions and Methods for Treatment of Prediabetes | CROSS III WILLIAM H (US) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310461-A1 | Compositions and Methods for Treatment of Prediabetes | GPX1, GPX4, NFE2L2 | PTGS1 820/4885KCNH2 4318/4885VNN1 2783/4885 |
| US-20170312329-A1 | Compositions and Methods for Treatment of Prediabetes | GPX4, LPO, GPX1 | PTGS1 1442/4885KCNH2 3274/4885VNN1 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.